drugset / Trial / NCT01435330

Safety and Tolerability of BVS857 in Subjects With Insulin Resistance

NCT01435330 ↗

Phase 1 Completed 43 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blind

Summary

The study will assess the safety, tolerability, drug label and effect in subjects with and without insulin resistance.

Timeline

Start
2011-03
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BVS857 Unknown — Other

Indications

No indication recorded.